⌘K
t
Philip Broadley, a Non-Executive Director of AstraZeneca PLC, gifted 5,735 ordinary shares of $0.25 each in the Company to his spouse. This transaction, for nil consideration, occurred on 17 December 2025.
| Date | 19 Dec 2025 |
| Time | 11:00:00 |
| Category | Director/PDMR dealings |
| ID | 2061M |
19 December 2025
Transaction by Person Discharging Managerial Responsibilities and Person Closely Associated
AstraZeneca PLC (the Company) announces that, on 17 December 2025, it was notified by Philip Broadley, Non-Executive Director, that on 17 December 2025, Mr Broadley gifted 5,735 ordinary shares of $0.25 each in the Company, for nil consideration, to his spouse, who is a person closely associated (PCA) to Mr Broadley.
Further details are set out in the attached notifications, made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018.
|
1
|
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a)
|
Name |
Philip Broadley |
||||
|
2
|
Reason for the notification
|
|||||
|
a)
|
Position/status
|
Non-Executive Director and PDMR |
||||
|
b)
|
Initial notification /Amendment |
Initial notification |
||||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a)
|
Name |
AstraZeneca PLC |
||||
|
b)
|
LEI |
PY6ZZQWO2IZFZC3IOL08 |
||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a)
|
Description of the financial instrument, type of instrument
Identification code |
Ordinary Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
|
||||
|
b)
|
Nature of the transaction
|
Gift of shares for nil consideration |
||||
|
c)
|
Price(s) and volume(s)
|
|
||||
|
d)
|
Aggregated information
- Aggregated volume - Price |
Not applicable - single transaction
|
||||
|
e)
|
Date of the transaction
|
17 December 2025 |
||||
|
f)
|
Place of the transaction
|
Outside a trading venue |
||||
|
1
|
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a)
|
Name |
Gillian Broadley |
||||
|
2
|
Reason for the notification
|
|||||
|
a)
|
Position/status
|
Person Closely Associated (PCA) to Philip Broadley (PDMR) |
||||
|
b)
|
Initial notification /Amendment |
Initial notification |
||||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a)
|
Name |
AstraZeneca PLC |
||||
|
b)
|
LEI |
PY6ZZQWO2IZFZC3IOL08 |
||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a)
|
Description of the financial instrument, type of instrument
Identification code |
Ordinary Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
|
||||
|
b)
|
Nature of the transaction
|
Receipt of gift of shares for nil consideration |
||||
|
c)
|
Price(s) and volume(s)
|
|
||||
|
d)
|
Aggregated information
- Aggregated volume - Price |
Not applicable - single transaction
|
||||
|
e)
|
Date of the transaction
|
17 December 2025 |
||||
|
f)
|
Place of the transaction
|
Outside a trading venue |
||||
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit www.astrazeneca.com and follow the Company on social media @AstraZeneca.
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Matthew Bowden
Company Secretary
AstraZeneca PLC